688310.SH
迈得医疗
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 15.05
−4.14%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 447.1M | 447.4M | 274.9M | 480.2M | 383.5M |
| Cost of Revenue | 248.7M | 247.6M | 154.3M | 233.8M | 190.0M |
| Gross Profit | 198.4M | 199.8M | 120.5M | 246.4M | 193.5M |
| Operating Expenses | |||||
| R&D Expense | 49.8M | 47.2M | 40.4M | 33.2M | 36.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 77.3M | 77.8M | 95.2M | 90.4M | 75.6M |
| Selling & Marketing Expense | 40.2M | 35.5M | 25.0M | 27.6M | 18.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 175.8M | 167.1M | 164.2M | 150.5M | 123.4M |
| Cost and Expenses | 424.5M | 414.7M | 318.5M | 384.3M | 313.4M |
| Operating Income (EBIT) | 51.0M | 59.4M | (27.4M) | 128.0M | 86.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 50.4M | 60.9M | (29.2M) | 127.4M | 87.2M |
| Income Tax Expense | 17.0M | 16.4M | 780.7K | 17.8M | 10.2M |
| Bottom Line | |||||
| Net Income | 56.7M | 64.9M | (20.0M) | 99.8M | 67.0M |
| Earnings from Cont. Ops | 33.4M | 44.6M | (30.0M) | 109.6M | 77.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 56.7M | 64.9M | (20.0M) | 99.8M | 67.0M |
| Per Share | |||||
| Basic EPS | CN¥0.35 | CN¥0.40 | (CN¥0.12) | CN¥0.61 | CN¥0.57 |
| Diluted EPS | CN¥0.35 | CN¥0.40 | (CN¥0.12) | CN¥0.60 | CN¥0.57 |
| Revenue Per Share | CN¥2.82 | CN¥2.76 | CN¥1.65 | CN¥2.93 | CN¥3.26 |
| Shares | |||||
| Basic Shares Outstanding | 158.6M | 162.4M | 166.5M | 163.7M | 117.6M |
| Diluted Shares Outstanding | 158.6M | 162.4M | 166.5M | 163.7M | 117.6M |
| Profitability Metrics | |||||
| EBITDA | — | 99.5M | 4.4M | 156.5M | 102.2M |
| D&A | — | 40.1M | 31.8M | 28.5M | 15.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026